CLINICAL_TRIALS
trial_result
· 2013-07-18
Clinical Trial Update: 506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Responded to Fludarabine or Alkylating Agents [Phase 2]
Summary
GlaxoSmithKline's agent 506U78 completed a Phase 2 trial in Chronic Lymphocytic Leukemia patients who failed fludarabine or alkylating therapy.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: GlaxoSmithKline | Conditions: Leukemia | Phase 2 | Status: COMPLETED